Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), was selected as a finalist for URAC's 2013 Best Practices in Health Care Consumer Engagement and Protection Awards. Prime was selected for its Controlled Substance Drug Utilization Review (DUR) program, which is part of the GuidedHealth® platform.
The Controlled Substance DUR program helps health plans and physicians identify potential misuse and abuse of controlled substance medications. Doing so helps improve patient health and reduce health care costs. This is Prime's most widely used DUR program. It has been implemented by most of Prime's clients, including Florida Blue whose positive results were featured in the submission.
"Prime is honored to be named as a finalist for Best Practices in Health Care Consumer Engagement and Protection from URAC," said Eric Elliott, president and CEO at Prime Therapeutics. "This recognition validates the innovative work we've done to develop and implement an industry best practice for improving safety and lowering overall cost of care for our members."
A promising visual sign for concussion diagnosis in athletes